Established in 2006 by the merger of two 100-year-old Japanese pharmaceutical companies, Daiichi Sankyo, Inc. inherited a rich legacy of innovation and scientific expertise across therapeutic categories. Today, we’re just as dedicated to improving quality of life for the patients who need our medicines as our founders were a century ago. Our scientific expertise, robust pipeline and collaborative and ethical culture make a world of difference in the lives of patients, employees, and in the communities in which we live and work.
Contact details
Address: 24th Floor, United Center Bldg., 323, Silom Road, Silom, Bangrak, Bangkok 10500 Thailand
Tel: +662-631-2070
E-mail: Wilaipan.pan@daiichisankyo-th.com
website: http://www.dsi.com
Daiichi Sankyo Thailand’s managing director explains the Thai subsidiary’s success under his leadership, Thailand’s untapped potential as a regional economic center in Southeast Asia and his company’s role in providing high quality…
Servier Thailand’s general manager discusses the company’s competitive role in Thailand despite market challenges, the company’s ability to remain innovative and successful regardless of Thailand’s changing policies and Servier’s unique…
The Thailand Institute of Scientific and Technological Research’s (TISTR) governor shares the institute’s role in facilitating R&D, the use of herbal medicine in Thailand and the future growth of R&D…
Daiichi Sankyo Thailand’s managing director explains the Thai subsidiary’s success under his leadership, Thailand’s untapped potential as a regional economic center in Southeast Asia and his company’s role in providing high quality…
PReMA’s CEO discusses the association’s role within the industry as an organization that is improving the healthcare system in Thailand and on helping companies in the pharmaceutical industry bring innovation and…
As one of the figureheads of the BIOTECh industry in Thailand, could you introduce your background to our readers? I was trained as a biochemist in Thailand, and did my…
Pharmaceutical Executive, highlighting the milestones in the company development since you took over five years ago? Unilab is the biggest pharmaceutical company in the Philippines, with a market share of…
Indochina’s biggest pharmaceutical market (US$ 4 billion, 66 million population, <5 percent of GDP spent on healthcare) has quickly matured over the past years due to the implementation of…
You moved from the post of President for Sanofi Pasteur in Korea to President of Sanofi Pasteur in Thailand 1,5 years back. What have been the milestones so far and…
Asia is rapidly becoming a new frontier for drug development as Western companies seek to develop and register their products in Asia, while emerging Asian companies seek new capabilities to…
Dr. Seeto, this is your first head of country position for AZ! Looking back at your first year-and-a-month, what have been the highlights and the key lessons learnt? Firstly, leading…
Dr. Witit, when we interviewed your predecessor in 2006, we talked about the vital role and leading position GPO plays in the Thai pharmaceutical industry and the company’s investments in…
‘When markets are inefficient, relationships are important. When markets are more efficient, relationships become less important because the markets become more systematic, professional, and objective in the way they operate,’…
See our Cookie Privacy Policy Here
